This work is aimed at describing the workflow for a methodology that combines chemoinformatics and pharmacoepidemiology methods and at reporting the first predictive model developed with this methodology. The new model is able to predict complex networks of AIDS prevalence in the US counties, taking into consideration the social determinants and activity/structure of anti-HIV drugs in preclinical assays. We trained different Artificial Neural Networks (ANNs) using as input information indices of social networks and molecular graphs. We used a Shannon information index based on the Gini coefficient to quantify the effect of income inequality in the social network. We obtained the data on AIDS prevalence and the Gini coefficient from the AIDSVu database of Emory University. We also used the Balaban information indices to quantify changes in the chemical structure of anti-HIV drugs. We obtained the data on anti-HIV drug activity and structure (SMILE codes) from the ChEMBL database. Last, we used Box-Jenkins moving average operators to quantify information about the deviations of drugs with respect to data subsets of reference (targets, organisms, experimental parameters, protocols). The best model found was a Linear Neural Network (LNN) with values of Accuracy, Specificity, and Sensitivity above 0.76 and AUROC > 0.80 in training and external validation series. This model generates a complex network of AIDS prevalence in the US at county level with respect to the preclinical activity of anti-HIV drugs in preclinical assays. To train/validate the model and predict the complex network we needed to analyze 43
Introduction
The acquired immunodeficiency syndrome (AIDS) (1) caused by the human immunodeficiency virus (HIV) is still considered as one of the most life-threatening diseases, and the HIV(2, 3) pandemic continues to spread. Since the beginning of the epidemic, more than 60 million people have been infected with HIV, and over 25 million have died from the disease. Since the first case of AIDS was reported by the US in 1981, tremendous progress has been made in the prevention and treatment of HIV/AIDS,(4) especially in the development of antiretroviral therapy(5) that has proven to be life-saving to millions of people. Therefore, the discovery and development of novel, highly potent anti-HIV drugs remain imperative, although the eradication is still a difficult goal to achieve due to a low level of viral persistence in treated subjects. (6) In this context, different Computer-Aided Drug Design (CADD) techniques, useful to predict the behavior of anti-HIV drugs, may play an important role in reducing the number of preclinical and clinical studies. For instance, we could use chemoinformatics models that link the chemical structure of drugs with their biological activity. In fact, there are many reports of chemoinformatics models, useful to predict anti-HIV activity in preclinical assays. (7) In principle, we could upgrade these models to predict the anti-HIV activity of drugs not only in preclinical screening but also in clinical and pharmacoepidemiology studies. Such a model may become a very useful tool not only for the Pharmaceutical Industry in order to reduce clinical assays. They should ideally be useful also for Public entities responsible for implementation of Health policies in the phase IV of drug development. However, there are no reports of models useful to predict the performance of anti-HIV drugs in both preclinical and pharmacoepidemiology studies on large populations without carrying out clinical studies. We neither had at our disposal models able to extrapolate, at least, the performance of anti-HIV drugs from preclinical studies to epidemiology studies on large populations without carrying out clinical studies.
A useful chemoinformatics-pharmacoepidemiology model should be multilevel by definition as it is expected to account for both molecular and population structure. It means that, in order to develop such computational models, we need to process different types of input data coming from many different levels of organization of matter. On the one hand, we need to introduce information about the anti-HIV drugs including at least the chemical structure of the drug (level i) and the preclinical assay information, such as biological targets (level ii), organisms (level iii), or assay protocols (level iv). On the other hand, we need to incorporate population structure descriptors (level v) that quantify the epidemiological and social and economic factors affecting the population selected for the study. Last, as populations in modern society are not close systems we should also quantify the effect of interaction of the population under study with other populations that may influence the pharmacoepidemiology study (level vi). The data for levels i--iv were obtained from public databases of biological activity of organic compounds. These databases accumulated immense data sets of experimental results of pharmacological trials for many compounds. For instance, ChEMBL (https://www.ebi.ac.uk/chembl/) (8, 9 ) is one of the biggest with more than 11,420,000 activity data for >1,295,500 compounds and 9,844 targets. Specifically, ChEMBL contains >43,000 outcomes for assays of anti-HIV compounds.
The formulation of mathematical models of this large data set from ChEMBL is very complex per se(9, 11) but becomes an even more complicated problem when AIDSVu data are added. This is not only a problem of analysis of a huge number of data points (Big Data), (12) (13) (14) (15) (16) (17) it is also a problem of dealing with the mathematical representation/codification of such diverse information from many different levels of organization of matter and areas of scientific knowledge. We can talk about three features of the problem resulting from the combination of chemical, pharmacological, and epidemiological information: (1) multitargeting, (2) multiobjective, and/or (3) multiscaling features. The multitargeting nature of the problem (18) (19) (20) refers to the existence of multitarget compounds that can interact with more than one molecular or cellular target. The multiobjective optimization problem (MOOP) (21) (22) (23) (24) (25) refers to the necessity of prediction/optimization of results for different experimental measures obtained in different pharmacological assays. Last, multiscaling refers to the different structural levels of the organization (i-vi) of matter that input variables. It means that we need to develop models able to link the changes in the AIDS prevalence in a given a th population with the changes in the biological activity of the q th drug (d q ), due to variations in the chemical structure, detected in preclinical assays carried out under a set of j th conditions (c j ).
We can use numerical descriptors of the molecular graph of the drug. In particular, some of these parameters are useful to quantify information about the properties of molecular, biological, and/or social systems (information measures). For instance, Shannon's entropy measures are universal parameters used to codify biologically relevant information in many systems. In the 1970s Bonchev and Trinajstic et al. published some works about the use of Shannon's entropy to calculate a structural information parameter. (26) (27) (28) (29) Kier published other seminar works on the use of Shannon's entropy to encode molecular structure in chemoinformatics studies in 1980. (29) In this context, a drug molecule is considered an information source. Many other authors used Shannon's entropy parameters to encode small molecule structure.(30-35) Graham et al. (36) (37) (38) (39) (40) used entropy measures to study in depth the information properties of organic molecules. These concepts were extended to describe protein, (41, 42) DNA sequences, (43) or protein-protein interaction networks.(44) Mikoláš et al. (45) reviewed several studies about the use of entropy measures in functional magnetic resonance. In a recent work we have used Shannon entropy measures and the idea of Moving Average (MA) operators in a time series analysis with a similar purpose.(46) Additionally, information indices are graph-theoretical invariants that view the molecular graph as a source of different probability distributions to which information theory definitions can be applied. They can be considered a quantitative measure of the lack of structural homogeneity or the diversity of a graph, in this way being related to the symmetry associated with structure.(47-49) Ivanciuc and Balaban(50) defined the indices for simple and weighted molecular graphs and tested the information theory-indices for modeling alkane densities. Moreover, Ivanciuc et al.(51) also found that the information indices were extended for any symmetric molecular matrix derived from vertex-and edge-weighted molecular graphs. Dehmer et al. (52) (53) (54) (55) mentioned the Balaban information indices (56) in their work about novel topological descriptors for biological networks.
However, the codification of the molecular structure of the drug is only the first step here. We have information about a high number of assays carried out in very different conditions (c j ) for the same or different targets, which may be molecular or not. The nonstructural information herein refers to different assay conditions (c j ) like time, concentrations, temperature, cellular targets, tissues, organisms, etc. A possible solution may rely upon the use of the idea of MA operators used in a time series analysis with a similar purpose.(46) MA models became popular after the initial works conducted by Box and Jenkins.(57) In a time series analysis, MA models may combine other operators I = Integrated, AR = Autoregressive, N = Nonlinear operators, or X = Exogenous effects. In this sense, we can develop models like ARMA, ARIMA, VARIMA, ARIMAX, NARMA, etc., combining different operators. The MA operators used in time series are the average value of a characteristic of the system for different intervals of time or seasons. In multiobjective modeling, we calculate the MA operators as the average of the property of the system (molecular descriptors or others) for all drugs or targets with a specific response in an assay carried out at under a subset of conditions (c j ). Consequently, our MA operator does not act over a time domain but over a subset of conditions of the pharmacological assays. Last, we can use these information descriptors and MA operators as inputs for a Machine Learning (ML) algorithm. This ML has to seek the coefficients of the ALMA model able predict the correct links in L. The neural network approximates the operation of the human brain, (62, 63) and this initially ″trained″ or fed large amounts of data and rules about data relationships. ANNs are in general nonlinear algorithms with a high number of processors (called neurons) which, in a classic picture, are distributed in layers and act in parallel (neurons in the same layer) or in series (pairs of neurons connected in different layers). In recent years, ANNs (64, 65) have turned out to be a powerful method for various practical applications in a great variety of disciplines, and they can be used to find complex relationships between inputs and outputs or to find models in data. Another aspect of ANNs (66, 67) is that there are different architectures, which require different types of algorithms for training; the trained ANN do not need to be reprogrammed.
Materials and Methods

Linear and Nonlinear ALMA Models
The ALMA models are useful to assess the formation of links in different complex networks that are representations of complex systems. They are adaptable to all types of molecular descriptors and/or graphs invariants or descriptors for complex networks. In this work, we tried to seek a classification model. The overall output of this model is L aq (c j ) pred . This variable is a prediction of the observed variable L aq (c j ) obs . Both the observed and predicted variables are discrete Boolean variables (1, 0). The observed variable takes the value L aq (c j ) obs = 1 if the observed score S aq (c j ) obs > input cutoff or L aq (c j ) obs = 0 otherwise. In analogy, the predicted variable L aq (c j ) pred = 1 if the predicted score S aq (c j ) pred > output cutoff or L aq (c j ) pred = 0 otherwise.
More specifically, we can say that the value is L aq (c j ) obs = 1 when the S aq (c j ) obs = Drug-Disease Ratio = DDR aq (c j ) > cutoff and L aq (c j ) obs = 0 otherwise. We defined the ratio as follows:
is the value of biological activity (EC 50 , IC 50 , K i , ..., etc.) reported in the ChEMBL database for the q th drug assayed under the set of conditions c j = (c l , c 2 , c 3 , c 4 ). The parameter δ j is similar to a Kronecker delta function. The parameter δ j = 1 when the biological activity parameter v q (c j ) is directly proportional to the biological effect (e.g., K i values, Activity (%) values, etc.). Conversely, δ j = −1 when the biological activity parameter v q (c j ) is in inverse proportion to the biological effect (e.g., EC 50 values, IC 50 values, etc.). The parameter z q (c j ) is the z-score of the biological activity that depends on the functions AVG and SD. These functions are the average and standard deviation of v q (c j ) for all drugs assayed under the same conditions. In this sense, c 1 = is the experimental measure of activity, c 2 = is the protein target, c 3 = is the organism that expresses the target, and c 4 = is the assay protocol per se. In the denominator, we used the term D a that is the AIDS prevalence rate for the a th county. We can conclude that L aq (c j ) obs and consequently L aq (c j ) pred depend on both the prevalence of the disease and the effectiveness of the drug due to the definition of DDR aq (c j ). In Table 1 , c 2 , c 3 , c 4 ) . In addition, ⟨D q (c j )⟩ is the average value of the biological activity for all the drugs assayed under the same conditions. Consequently, ΔD q (c j ) is an MA operator that accounts for the deviation of the biological activity of the drug D q (c j ) in a preclinical assay with respect to the average value ⟨D q (c j )⟩ of this activity for all drugs assayed under the same conditions c j .
In order to seek a model able to predict L aq (c j ) pred , we used as input different information descriptors for drugs and populations. In general, we refer to an information index I The reader should note that the predicted, output, or dependent variable S aq (c j ) is not a discrete variable but a real-valued numerical score. However, the variable S aq (c j ) is directly proportional to the observed variable (L aq ). Please, note that all the parameters S aq (c j ) => L aq (c j ) => DDR aq (c j ) => D q (c j ) form a series that in the last instance depends on (=>) the conditions of the initial preclinical assay used to measure the activity of the drug c j = (c l , c 2 , c 3 , c 4 ). In general, c j refers to different boundary conditions for the assay, e.g., targets, assays, cellular lines, organisms, organs, etc. In this sense, c 1 = is the experimental measure of activity, c 2 = is the protein target, c 3 = is the organism that expresses the target, and c 4 = is the assay protocol per se. Some inputs of the models depend on parameters of the type of deviations ΔI 
CHEMBL Data Set of Drugs
We downloaded from the public database CHEMBL a general data set composed of >8,000 multiplexing assay end points (results of multiple assays). (8, 9) The data set used to perform the model included N = 43,249 statistical cases made up of N d = 21,582 unique drugs. These drugs have been assayed one by one in at least one out of 10 possible standard type measures determined in at least one out of 4,856 different assays (experimental protocols reported as different in ChEMBL). Each assay involved, in turn, at least one out of 9 nonmolecular or protein targets expressed in tissues, cells, or viral particles of at least one out of 5 different organisms (including human cells lines).
Balaban Information Indices of Molecular Graphs of Drugs
The Balaban information indices(56) U, V, X, and Y are very useful to quantify information about the chemical structure of drugs.(71) These indices use some the following parameters: σ x = vertex distance degree of x th atom (i.e., sum of topological distances from the considered atom to any other atom), d xy is the topological distance between atoms x th and y th atoms; n is the number of non-H atoms. Other parameters used are g f x = the number of distances from the x th vertex equal to g and η x = the eccentricity of the x th atom (i.e., the maximum topological distance from the considered atom). We denoted these indices in the present work as I q k . In this notation, the letter I stands for the information index, q indicates the number of order (label) of the drug in the data set, and k indicates the type of index. The mathematical formulas for calculation of these indices are
AIDSvu Data Set of AIDS Prevalence in the US at County Level
Data were drawn from the AIDSVu database of the Rollins School of Public Health at Emory University (www.aidsvu.org). We downloaded the values of epidemiological variables for AIDS in the US at county level from the public database. The values used in this study included the percentage of adults/adolescents living with an HIV diagnosis in 2010 per 100,000 populations. The county-level HIV surveillance data displayed on AIDSVu are estimated data for persons aged 13 and older living with an HIV infection diagnosis. All race groups are non-Hispanic, and the Hispanic/Latino ethnicity is inclusive of all races. Sex is defined as "sex at birth". Data are not displayed at the county level for Asians, Native Hawaiians/Other Pacific Islanders, and American Indians/Alaska Natives because these data do not meet CDC's criteria for statistical reliability, data quality, or confidentiality due to small population denominators and HIV case counts. The total number of counties is n a = 2,310.
Shannon Information Indices of Income Inequality
We can calculate an information index to quantify the possibility of AIDS spreading/prevalence in different counties (a) of the US. Let be an initial situation in which each county has a value of AIDS prevalence rate D a at the initial time (t 0 = 2010). We used here a simple information index I a 0 (t) for income inequality in the different counties that year. This index depends on the probability 0 p a with which the county presents certain income inequality. We set here this probability 
Definition of the Algorithm
In this work, we report for the first time a model based on information indices of chemical structure, biological assay, and county level income inequality. The model is able to link the deviations in the AIDS prevalence in the a th county with the changes in the biological activity of the q th drug (d q ). In so doing, the model considers the biological activity of anti-HIV compounds detected in preclinical assays carried out under a set of j th conditions (c j ). Using this type of model, we can predict the pharmacoepidemiology complex network for AIDS in the United States at county level.
First, we propose a new algorithm to construct this type of models. The algorithm/model used as input both drug structures and preclinical information as well as county income inequality data. We understand here as algorithm the series of all steps given in different stages in order to seek and use the model. We illustrate the different steps of this algorithm in Figure 1 
Model Training and Validation
In the first step, we calculated the values drug-disease ratio DDR aq (c j ) obs for the 43,249 drugcounty pairs. After that, we carried out a cutoff scanning and found that we can split the data set into 11,089 cases with L aq (c j ) obs = 1 and 32,160 cases with L aq (c j ) obs = 0 using a cutoff = 500. This is 25.6% of the positive cases that ensure a ratio of above 1/4 of positive vs control cases. The data set used to train the model includes N = 32,437 statistical cases. The data set used to validate the model includes N = 10,812 statistical cases. The cases used in the validation set (external validation set) were never used to train the model. Overall, training + validation sets include N = 43,249 statistical cases. Next, we calculated the values of the Balaban information indices I q k for all the drugs/organic compounds present in our ChEMBL subset (step a.2). Table 2 shows some examples of these values I q k for known drugs. In addition, in Table SM1 Table 3 , you can see some examples of these average values for different boundary conditions like targets, organisms, etc. After a visual inspection, one can note that the ⟨I q 1 ⟩ values seem to distinguish more clearly between the different boundary conditions. For instance, they have differences in the range of 10-100 units for 9 different protein targets (4 HIV vs five human proteins) present in the data set. However, the other averages <I q k > with k > 1 seem to be worse at differentiating the proteins. In Table SM2 of the Supporting Information, we list the values of <I Table 4 , we illustrate the values of I a 0 (t) for some counties of different states. In Table  SM3 of the Supporting Information, we list the values of I a 0 (t) for the 2,310 US counties studied here. The sensitivity analysis allowed us to quantify (rank) and order (ratio) into a sequence the importance of the different chemoinformatics vs pharmacoepidemiology inputs. This kind of model may be useful to predict different situations of interest in pharmacoepidemiology. For instance, the model is able to identify when the same drugs present a strong effect on population epidemiology for different counties (L aq (c j ) pred = 1). Table 6 shows the predictions for some cases with the LNN model. In the table we can see that the model predicts L aq (c j ) pred =1 for Nevirapine (75) in different counties, which is a drug L aq (c j ) obs = 1 for these counties. In Table SM4 of the Supporting Information, we provide the results predicted with the LNN model for all the cases in training and external validation series. We used the sensitivity analysis of the ANN module implemented in STATISTICA to detect the parameters with the higher contribution to the model. We can conduct the sensitivity analysis on the inputs to one ANN by a STATISTICA Neural Networks algorithm. The sensitivity analysis ranks the order of input importance by treating each input variable in turn as if it were "unavailable".(82) It is defined a missing value substitution procedure, which allows predictions to be made in the absence of values for one or more inputs. To define the sensitivity of a particular variable X, the first run uses the network on a set of test cases and accumulates the network error. In the second step, the network is employed again using the same cases but replacing the observed values of X with the value estimated by the missing value procedure, and again it calculated the accumulated network error. By removing the variable X, it is expected for some deterioration in error to occur. Therefore, the measure of sensitivity is the ratio of the error with missing value substitution to the original error. The more sensitive the network is to a particular input, the greater the deterioration is expected, and therefore the greater the ratio. The elimination of a variable with ratio ≤1 improves or has no effect on the performance of the ANN. After the sensitivities are calculated, they are ranked in order. In Table 7 we can see that the model shows a higher relevance to the information about the molecular structure, parameters of type I q k . Second, the model ranks the information about the organism used to measure the biological activity, parameters of type ΔI q k (c 3 ). The third type of relevant input is the experimental measure used to quantify the activity of the drug, parameters of type ΔI q k (c 1 ). The fourth ranked inputs in order of importance are parameters of type ΔI q k (c 2 ), which quantify the target protein. The fifth type of input quantifies information about the assay protocol used to test the drug. The last effect introduced in the model was the information about income inequality in the county I a 0 (t). Thus, the sensitivity analysis shows that the model is ranked according to the importance of factors in the following order (AIDS epidemiology/anti-HIV drug) ≈ structure of drug > organism in preclinical assay > experimental measure of activity > drug target > pharmacological assay > county income inequality. Table 7 depicts the parameters in decreasing order of their contribution to the model (higher contribution => higher ratio => lower rank). The five parameters with higher contribution are the following: I Table 7) . We retrained the model using only these parameters, but the new ANN fails to generate good predictive models with Sp and Sn < 50%. It means that the model provides a greater importance to the chemical structure and pharmacological information (branch A), with respect to county information (branch B), but it needs all the parameters. This could be explained taking into consideration that branch A includes the higher number of input factors (information considered), whereas branch B includes only one input factor, the income-inequality in the county with respect to the state. We should also note that the only epidemiological feature used as input to calculate the Shannon information indices of the county was the G a measure of income inequality. The G a measure of income-inequality is widely used as a descriptor to approach the study of the epidemiology of different diseases. (83, 84) The values of G a ≈ 0 are characteristic of societies with near-to-ideal equalitarian distribution of income, whereas values of G a ≈ 1 are typical of inequality in income distribution. (85) It may indicate that possibly we should include other factors in branch B in order to collect additional epidemiological information relevant to the present problem. In upcoming papers we will continue working on the strategy described here, including other information indices of the molecules, other epidemiological factors, different disease transmission matrices, and using different types of machine learning algorithms. 
Conclusions
We developed a model called LNN-ALMA to generate complex networks of the AIDS prevalence in the US counties with respect to the preclinical activity of anti-HIV drugs. The best classifier found was the LNN; the inputs of this classifier are based on Balaban information indices. Consequently, this model may be useful to predict the most effective drugs to treat HIV in different populations (from the US counties) with a given epidemiological prevalence. In future work, we will continue to improve the models, and we will include other information indices, social and economic factors, machine-learning techniques, etc.
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